全文获取类型
收费全文 | 4511篇 |
免费 | 450篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 103篇 |
妇产科学 | 110篇 |
基础医学 | 522篇 |
口腔科学 | 72篇 |
临床医学 | 441篇 |
内科学 | 881篇 |
皮肤病学 | 48篇 |
神经病学 | 243篇 |
特种医学 | 180篇 |
外科学 | 684篇 |
综合类 | 140篇 |
预防医学 | 447篇 |
眼科学 | 188篇 |
药学 | 323篇 |
中国医学 | 97篇 |
肿瘤学 | 470篇 |
出版年
2023年 | 43篇 |
2022年 | 58篇 |
2021年 | 95篇 |
2020年 | 67篇 |
2019年 | 113篇 |
2018年 | 102篇 |
2017年 | 92篇 |
2016年 | 88篇 |
2015年 | 132篇 |
2014年 | 152篇 |
2013年 | 190篇 |
2012年 | 270篇 |
2011年 | 265篇 |
2010年 | 180篇 |
2009年 | 173篇 |
2008年 | 264篇 |
2007年 | 266篇 |
2006年 | 234篇 |
2005年 | 258篇 |
2004年 | 201篇 |
2003年 | 208篇 |
2002年 | 163篇 |
2001年 | 116篇 |
2000年 | 115篇 |
1999年 | 117篇 |
1998年 | 60篇 |
1997年 | 46篇 |
1996年 | 36篇 |
1995年 | 28篇 |
1994年 | 39篇 |
1993年 | 29篇 |
1992年 | 88篇 |
1991年 | 73篇 |
1990年 | 67篇 |
1989年 | 52篇 |
1988年 | 68篇 |
1987年 | 64篇 |
1986年 | 50篇 |
1985年 | 45篇 |
1984年 | 26篇 |
1983年 | 27篇 |
1982年 | 28篇 |
1981年 | 19篇 |
1980年 | 17篇 |
1979年 | 18篇 |
1978年 | 16篇 |
1976年 | 18篇 |
1974年 | 12篇 |
1972年 | 12篇 |
1970年 | 11篇 |
排序方式: 共有4981条查询结果,搜索用时 15 毫秒
51.
Thomas Powles Michael B. Atkins Bernard Escudier Robert J. Motzer Brian I. Rini Lawrence Fong Richard W. Joseph Sumanta K. Pal Mario Sznol John Hainsworth Walter M. Stadler Thomas E. Hutson Alain Ravaud Sergio Bracarda Cristina Suarez Toni K. Choueiri James Reeves Allen Cohn David F. McDermott 《European urology》2021,79(5):665-673
BackgroundThe use of immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted therapy as second-line treatment for metastatic clear cell renal cancer (mRCC) has not been evaluated prospectively.ObjectiveTo evaluate the efficacy and safety of atezolizumab + bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with mRCC.Design, setting, and participantsIMmotion150 was a multicenter, randomized, open-label, phase 2 study of patients with untreated mRCC. Patients randomized to the atezolizumab or sunitinib arm who had investigator-assessed progression as per RECIST 1.1 could be treated with second-line atezolizumab + bevacizumab.InterventionPatients received atezolizumab 1200 mg intravenously (IV) plus bevacizumab 15 mg/kg IV every 3 wk following disease progression on either atezolizumab or sunitinib monotherapy.Outcome measurements and statistical analysisThe secondary endpoints analyzed during the second-line part of IMmotion150 included objective response rate (ORR), progression-free survival (PFS), and safety. PFS was examined using Kaplan-Meier methods.Results and limitationsFifty-nine patients in the atezolizumab arm and 78 in the sunitinib arm were eligible, and 103 initiated second-line atezolizumab + bevacizumab (atezolizumab arm, n = 44; sunitinib arm, n = 59). ORR (95% confidence interval [CI]) was 27% (19–37%). The median PFS (95% CI) from the start of second line was 8.7 (5.6–13.7) mo. The median event follow-up duration was 19.4 (12.9–21.9) mo among the 25 patients without a PFS event. Eighty-six (83%) patients had treatment-related adverse events; 31 of 103 (30%) had grade 3/4 events. Limitations were the small sample size and selection for progressors.ConclusionsThe atezolizumab + bevacizumab combination had activity and was tolerable in patients with progression on atezolizumab or sunitinib. Further studies are needed to investigate sequencing strategies in mRCC.Patient summaryPatients with advanced kidney cancer whose disease had worsened during treatment with atezolizumab or sunitinib began second-line treatment with atezolizumab + bevacizumab. Tumors shrank in more than one-quarter of patients treated with this combination, and side effects were manageable. 相似文献
52.
Yinshi Ren Zhuo Deng Vishal Gokani Michael Kutschke Thomas Wesley Mitchell Olumide Aruwajoye Naga Suresh Adapala Nobuhiro Kamiya Yousef Abu-Amer Harry KW Kim 《Journal of bone and mineral research》2021,36(2):357-368
Legg-Calvé-Perthes disease (LCPD) is a juvenile form of ischemic femoral head osteonecrosis, which produces chronic hip synovitis, permanent femoral head deformity, and premature osteoarthritis. Currently, there is no medical therapy for LCPD. Interleukin-6 (IL-6) is significantly elevated in the synovial fluid of patients with LCPD. We hypothesize that IL-6 elevation promotes chronic hip synovitis and impairs bone healing after ischemic osteonecrosis. We set out to test if anti-IL-6 therapy using tocilizumab can decrease hip synovitis and improve bone healing in the piglet model of LCPD. Fourteen piglets were surgically induced with ischemic osteonecrosis and assigned to two groups: the no treatment group (n = 7) and the tocilizumab group (15 to 20 mg/kg, biweekly intravenous injection, n = 7). All animals were euthanized 8 weeks after the induction of osteonecrosis. Hip synovium and femoral heads were assessed for hip synovitis and bone healing using histology, micro-CT, and histomorphometry. The mean hip synovitis score and the number of synovial macrophages and vessels were significantly lower in the tocilizumab group compared with the no treatment group (p < .0001, p = .01, and p < .01, respectively). Micro-CT analysis of the femoral heads showed a significantly higher bone volume in the tocilizumab group compared with the no treatment group (p = .02). The histologic assessment revealed a significantly lower number of osteoclasts per bone surface (p < .001) in the tocilizumab group compared with the no treatment group. Moreover, fluorochrome labeling showed a significantly higher percent of mineralizing bone surface (p < .01), bone formation rate per bone surface (p < .01), and mineral apposition rate (p = .04) in the tocilizumab group. Taken together, tocilizumab therapy decreased hip synovitis and osteoclastic bone resorption and increased new bone formation after ischemic osteonecrosis. This study provides preclinical evidence that tocilizumab decreases synovitis and improves bone healing in a large animal model of LCPD. © 2020 American Society for Bone and Mineral Research (ASBMR). 相似文献
53.
54.
Fong Zhi Ven Sekigami Yurie Qadan Motaz Fernandez-del Castillo Carlos Warshaw Andrew L. Lillemoe Keith D. Ferrone Cristina R. 《Annals of surgical oncology》2021,28(8):4216-4224
Annals of Surgical Oncology - Long-term pancreatoduodenectomy (PD) survivors have previously reported favorable quality of life (QoL). However, there has been a paucity of studies utilizing... 相似文献
55.
56.
57.
7例尿毒症贫血患者在自发急性缺氧状态下,其血清红细胞生成素(EPO)浓度显著提高(平均7倍),且与PO2呈负相关。缺氧状态纠正后血清EPO浓度下降。提示尿毒症贫血患者的EPO氧依赖调控系统功能尚存在,但处于不敏感的低调状态。进一步了解其机遇,则可能通过促进内源性EPO的生成,有助于悄毒症贫血的治疗。 相似文献
58.
59.
Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage
C. R. Kumana M. Kou Y. L. Yu K. Y. Fong C. F. Fung C. M. Chang W. Mück I. J. Lauder 《European journal of clinical pharmacology》1993,45(4):363-366
Summary Nimodipine pharmacokinetics was investigated in 12 Chinese patients with acute subarachnoid haemorrhage receiving an IV infusion of 1.6 or 2 mg/h (based on estimated body weight) for 10 days. Peripheral venous blood samples were collected for up to 4 days and plasma nimodipine was assayed by GC/ECD. The mean value was taken as the steady state concentration (Css) and Clearance (CL) (hourly dose/Css) was calculated. Eight survivors were given oral nimodipine (60 or 90 mg) every 6h (based on body weight), blood was sampled over 6 h and the plasma nimodipine level determined. The values for Css, CL and CL·kg–1 were 33.5 g·l–1, 58 l·h–1 and 1.0 l·h–1·kg–1 respectively; in survivors receiving the drug orally, bioavailability of the 30 mg tablet was 9%. In one very sick patient given crushed tablets by naso-gastric tube, the AUC was very low; in vitro studies indicated that adsorption of nimodipine by the tubing was unlikely to have been the cause.The pharmacokinetic findings in Chinese patients are comparable to previously reported values in Caucasians. 相似文献
60.
This paper reports 25 kinds of polyclonal or monoclonal antibodies by ABC immunohistochemical technique used for 253 cell smears by fine-needle aspiration. The results were,1. Immunohistochemical diagnosis were classified into 136 metastatic cancers ( K12 EMA CEA LCA-),92 lymphomas (LCA k12- EMA- CEA-), 4 mesenchymal tumors (Vimentin ), 3 melanomas (S-100 NSE ). 15 reactive proliferations (k λ4 CD CD8 ) and 3 unspecified.2. The origin of 70 metastatic cancers were classified into 36 lung (HLC3-AB ), 4 gastrointestinal tract (MG7 ), 8 thyroid (TGB ), 1 prostate (PSA ), 3 liver (AFP ) and 14 unknown. 3. Immunologic phenotype of 87 lymphomas wereclassified into 66 cases of B-cell, 4 T-cell, 3 hsitocyte, 7 Hodgkin' s diseases and 7 unclear. The above results suggest that immunohistochemlcal method may be used as a new method of diagnosing and differentiating epithelial and non-epithelial tumors, detecting primary focus of metastatic cncer, differentiating between reactive proliferation adn lymphome a 相似文献